Sales Battle Card: Vicero, Inc. CMO Alert

🚀 Battle Card: Vicero, Inc.

• Han Myint, MD, FACP, Chief Medical Officer · 🔗 LinkedIn

• New CMO brings 30+ years advancing breakthrough oncology therapies from first-in-human studies through FDA approvals → Source

• Speeding IND-enabling studies for novel bispecific VHH VINCOBODIES

• Mitigating immune-related toxicities in early-stage solid tumor trials

• Primary: End-to-end clinical operations platform → accelerate first-in-human trials for VCR-036

• Expansion: Safety data analytics suite → minimize immune-related adverse events

• HQ: Cambridge, MA

• Employees: ≈ 50

• Rev: ≈ $5 M

• Website: vicerobio.com

🤼 Competitive Intel

• Parexel — CRO / Clinical Development
• Unique edge: Global regulatory & trial design expertise
• Evaluated by CMO & VP of Clinical Operations for IND readiness

• IQVIA — CRO / Data & Analytics
• Unique edge: Real-world data insights & massive patient recruitment
• Evaluated by CMO & Dir. of Biomedical Informatics for enrollment speed

• PPD — CRO / Full-service Trials
• Unique edge: Integrated lab services & global site network
• Evaluated by Chief Medical Officer for safety monitoring

• Labcorp — CRO / Safety Monitoring
• Unique edge: Centralized immunogenicity & biomarker labs
• Evaluated by CMO & Head of Quality for toxicity management

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑<your company>❑
OFFER_BRIEF   = ❑End-to-end clinical operations platform to accelerate first-in-human oncology trials❑
PROOF_METRIC  = ❑30% faster IND submission❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑punchy❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Han
COMPANY     = Vicero, Inc.
DEPT        = Clinical
SIZE        = ≈8
BOTTLENECK  = IND-enabling study delays
EVENT       = new CMO appointment
DETAIL      = Dr. Han Myint joining as CMO
PAIN        = speeding IND-enabling studies & mitigating immune-related toxicities
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250909324505&div=41152219
SIM_CO      = NexImmune
WIN_METRIC  = 30% faster trial startup
NEXT_SIZE   = ≈20
EMP_EST     = ≈50
REV_EST     = ≈$5M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈8-person Clinical

Han—noticed your Clinical team is ≈ 8.

That’s when IND-enabling study delays slows growth.

We helped NexImmune fix this with End-to-end clinical operations platform to accelerate first-in-human oncology trials.

Result: 30% faster trial startup.  
Quick call?

PS—next bottleneck hits ≈ 20.

DM ≤45 words, TONE:
Saw your post about Dr. Han Myint joining as CMO — speeding IND-enabling studies & mitigating immune-related toxicities.  
End-to-end clinical operations platform to accelerate first-in-human oncology trials. 30% faster IND submission.  
Quick chat?```